NeuroVigil, a San-Diego based company develops a miniaturized EEG system called iBrain, which detects the impact of drugs on the brain in patients with neurological diseases, and use unusual brain signals as potential biomarkers associated with harmful side effects. Roche, the Swiss pharmaceutical giant is currently testing the iBrain on drugs for Alzheimer’s, schizophrenia, and depression.
The classical way to getting an EEG to diagnose sleep disorders, which afflict 70 million people in the U.S., can involve going to a doctor or hospital, and wearing a cumbersome cap with something like thirty electrodes jutting out. The sensors transmit the brain’s electrical signals through multiple channels to a bulky recording machine.
NeuroVigil minimized these electrodes down to two, and the number of data channels to one. It is hooked up to a recording box smaller than an iPod, and lighter than a pack of cigarettes. The patient wears a soft elastic strap to secure the iBrain in place. The recording is done at home, and brain data can be downloaded to a computer and sent to NeuroVigil for analysis.
Read the full story on blogs.forbes.com